NR3C1 and prostate cancer: Various mechanisms of docetaxel-resistant exist in prostate cancer, such as ABC transporters [36, 37], glucocorticoid receptor (GR) [38], androgen receptor (AR) splicing [39, 40], epithelial plasticity [41, 42] and stem cells [43].